Collaborative Framework Agreement
28 7월 2009 - 5:25PM
RNS Non-Regulatory
TIDMPYN
Phynova Group PLC
28 July 2009
28 July 2009
Phynova Group PLC
("Phynova" or the "Company")
Phynova Announces Collaboration with Chrysalis Health & Beauty Solutions
Limited ("Chrysalis") to Promote and Commercialise Candidate Functional
Ingredient and Over the Counter ("OTC") Products in Europe
Phynova (AIM: PYN), the developer of prescription pharmaceuticals, functional
ingredients for the cosmetic, food and supplement industries and OTC products
capable of being registered under the Traditional Herbal Medicinal Products
scheme, today announces that it has signed a Collaborative Framework Agreement
with Chrysalis. Chrysalis is a specialist company based in Nottingham providing
consultation services and products to the Health and Beauty sectors.
Under the agreement Phynova will use Chrysalis' services over the next two years
for the promotion and commercialisation of Phynova's functional ingredient and
OTC product candidates in Europe. Phynova's product candidates include 'BCL-6',
a skin anti-ageing ingredient, and other functional food ingredients with
potential in the treatment of Type II diabetes and in combating fatigue and
improving sleep quality in middle aged and older people. Phynova is
collaborating in the development of these products with its joint venture
partner in China, Botanic Century Beijing Ltd ("BCCL") and has a collaboration
with Tasly Modern Chinese Medicine Resource Ltd, a subsidiary of the Tasly Group
of Tianjin, China, one of the world's largest producers of botanical drugs.
Phynova is also developing products suitable for registration under the EU's
Traditional Herbal Medicinal Products (THMP) scheme and is already in discussion
with a number of companies seeking to create new brands or to maintain OTC
herbal products on the market in compliance with the EU Directive's 2011
deadline for registration.
Phynova's CEO Robert Miller commented "As we have reported previously Phynova is
developing several pipeline opportunities capable of generating near term
revenues in the functional ingredient and OTC markets. With this agreement we
believe we have added greatly to our chances of achieving commercial success.
The team at Chrysalis supplies us strong complementary capabilities, with
support in areas such as formulation and pricing, proof of efficacy testing,
ingredient and product promotion and brand development. We believe Chrysalis
will help shorten the time to achieving commercial success on the path that
begins with our own discoveries and those of our collaborators in China."
For further information, please contact:
+-------------------------------------+-------------------------------------+
| Phynova Group PLC | |
+-------------------------------------+-------------------------------------+
| Robert Miller (CEO) | +44 (0) 1993 880700 |
+-------------------------------------+-------------------------------------+
| Tony Mills (CCO) | |
+-------------------------------------+-------------------------------------+
| | |
+-------------------------------------+-------------------------------------+
| Nominated Adviser and Broker: | |
+-------------------------------------+-------------------------------------+
| John East & Partners Limited, a subsidiary of Merchant Securities PLC |
+---------------------------------------------------------------------------+
| John East/Simon Clements | +44 (0) 20 7628 2200 |
+-------------------------------------+-------------------------------------+
Notes to Editors:
About Phynova
Phynova is a UK company developing new prescription pharmaceuticals derived from
plants used in Chinese medicines, functional ingredients for the cosmetic, food
and supplement industries and OTC products capable of being registered under the
Traditional Herbal Medicinal Products scheme.
For further information please visit www.phynova.com.
About Chrysalis Health & Beauty
Chrysalis Health & Beauty is a UK company specialising in the commercialisation
of new products and concepts for use in the Health & Beauty markets. With
extensive in-house technical and marketing experience, Chrysalis works with
academic, research-orientated and marketing-based organisations offering clear
routes to market and numerous services. Clients vary from businesses requiring
advice and assistance in taking a new product to market, to companies wishing to
outsource the entire commercial aspects of particular projects. With a worldwide
network of partners, Chrysalis can help to launch products on a global scale
rapidly and effectively. Chrysalis' typical clients include Brands, R&D
companies, Retailers and Manufacturers of raw materials or finished goods.
For further information please visit www.chrysalisweb.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRARPMPTMMTTMIL
Phynova (LSE:PYN)
과거 데이터 주식 차트
부터 1월(1) 2025 으로 2월(2) 2025
Phynova (LSE:PYN)
과거 데이터 주식 차트
부터 2월(2) 2024 으로 2월(2) 2025
Phynova (런던증권거래소)의 실시간 뉴스: 최근 기사 0
More Phynova News Articles